



Qlife has submitted a scientific study of the company's COVID-19 test for peer-review to be published in an international journal

Qlife announces today that a scientific study of the company's COVID-19 test has been submitted to Natures *Scientific Reports* for publication. The study demonstrates the potential of Qlife's mobile test platform Egoo.Health and COVID-19 tests that can deliver exactly the same clinical quality as laboratory tests in 30 minutes.

Today, most people get their diagnosis through so-called quantitative polymerase chain reaction (qRT-PCR) which is performed in specialized laboratories. This means that it often takes more than 24 hours from test to diagnosis.

The study, which has been submitted to Natures *Scientific Reports*, contains the first data from the mobile testing platform Egoo.Health and shows that Qlife's COVID-19 test offers an alternative to traditional qRT-PCR assays. Qlife's COVID-19 test, based on the NAAT/RT-SIBA technology, is performed with throat swab and can deliver test results with almost the same sensitivity and specificity as laboratory tests (qRT-PCR) in 30 minutes without specialized laboratory equipment.

"We need faster, more accessible and scalable diagnostics. The study shows that our mobile testing platform Egoo.Health can deliver reliable tests in the most vulnerable environments. Through the publication in *Scientific Reports*, we hope to achieve greater interest and a broader support for increased and decentralized test capacity and to demonstrate the benefits it can have for public health", says Peter Warthoe, Chief Scientific Officer at Qlife.

The study was led by virologist Phd. Maiken Worsøe Rosenstjerne, a former senior scientist at Statens Serum Institute (SSI), who is now Director of Assay Development at Qlife. Qlife's research team validated the RT-SIBA technology in collaboration with two Danish hospitals.

Read a pre-print of the article here: <https://www.researchsquare.com/article/rs-654239/v1>

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on [Egoo.health](https://egoo.health), [Qlifeholding.com](https://qlifeholding.com) or follow us on [LinkedIn](https://www.linkedin.com/company/qlife).